ROCKVILLE, Md., Oct. 18 /PRNewswire/ -- Panacea Pharmaceuticals, Inc.
announced today that its President and CEO, Hossein A. Ghanbari, Ph.D., is
among the distinguished list of speakers at the 3rd World Knowledge Forum,
which is being held October 15 to 18 in Seoul, South Korea. Dr. Ghanbari's
presentation, which was given in the session entitled "Corporate Venturing:
Key Questions," discussed issues pertaining to corporate venturing and its
necessity within the current biotechnology and pharmaceutical market. The
presentation further described Panacea's value adding and venturing business
model as well as the Company's future venturing plans.
Hosted by the Maeil Business Newspaper, Korea's leading business media
group, the World Knowledge Forum's goal is to bridge the knowledge divide
between advanced countries and developing ones. Under the 2002 theme of
"Knowledge in a World of Risk: A Compass Towards New Prosperity," participants
take part in discussions on subjects ranging from an analysis of the
challenges facing the U.S. economy to corporate management in times of
uncertainty to predictions on new management practices of the future. Last
year, the forum attracted more than 1,000 delegates from business, academia,
and government from 20 countries. More information about the World Knowledge
Forum is available at http://www.wkforum.org .
About Panacea Pharmaceuticals
Panacea Pharmaceuticals, Inc. is an emerging biopharmaceutical company
focused on utilizing functional genomics and proteomics to develop
therapeutics and diagnostics for diseases with substantial unmet clinical
need. The Company's product development focus is on novel proteins and
biochemical pathways related to cellular regulation and cell cycle
abnormalities in oncology as well as neurodegenerative diseases, particularly
Alzheimer's disease and Parkinson's disease.
More information is available at http://www.PanaceaPharma.com .
Except for historical information presented in this press release, matters
discussed herein may constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are based on the opinions and estimates of management only
as of the date of this release and are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance, or achievements expressed or implied by such
statements. Factors that might cause such a difference include, but are not
limited to, uncertainties related to our access to capital, the progress,
costs, and results of any clinical trials undertaken by us, progress of our
research and development projects, and uncertainties related to whether our
product candidates would ultimately achieve commercial success. We do not
undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise unless
required by law.
Contact:
Panacea Pharmaceuticals, Inc.
Kasra Ghanbari, Chief Operating Officer
Phone 240-453-6295; FAX 240-465-0450
Kasra@PanaceaPharma.com
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.PanaceaPharma.com
CONTACT:
Kasra Ghanbari, Chief Operating Officer, of
Panacea Pharmaceuticals, Inc., +1-240-453-6295, fax:
+1-240-465-0450, or Kasra@PanaceaPharma.com
|
